Interleukin 1 alpha accelerates recovery of neutrophils and immune function in mice treated with sublethal dosages of cyclophosphamide and reduces tumor growth and lung metastases in cyclophosphamide treated tumor bearing mice
Shen R.N.; Wu B.; Wang W.X.; Lu L.; Broxmeyer H.E.
Experimental Hematology (Charlottesville) 20(6): 776
1992
ISSN/ISBN: 0301-472X Accession: 031992685
PDF emailed within 1 workday: $29.90
Related References
Prepolec, M.; Wrone Smith, T.; Van Buren, E.; Lerman, S. 1993: Enhanced CD4-positive lymphocyte activation after CD8-positive cell depletion of cyclophosphamide -treated lymphoma-bearing SJL/J mice accelerates tumor growth Journal of Immunology 150(8 Part 2): 310ASchlick, E.; Ruffmann, R.; Chirigos, M.A.; Welker, R.D.; Herberman, R.B. 1985: In vivo modulation of myelopoiesis and immune functions by maleic anhydride divinyl ether copolymer (MVE-2) in tumor-free and MBL-2 tumor-bearing mice treated with cyclophosphamide Cancer Research 45(3): 1108-1114
Zimecki, Mł.; Artym, J.; Ryng, Sław.; Obmińska-Mrukowicz, B. 2008: RM-11, an isoxazole derivative, accelerates restoration of the immune function in mice treated with cyclophosphamide Pharmacological Reports: Pr 60(2): 183-189
Fibbe, W.E.; van der Meer, J.W.; Falkenburg, J.H.; Hamilton, M.S.; Kluin, P.M.; Dinarello, C.A. 1989: A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia Experimental Hematology 17(7): 805-808
Wrone, T.; Thrush, G.; Lerman, S. 1991: Coculture of cd8 cells from tumor bearing cyclophosphamide cy treated sjl mice yields a suppressor factor FASEB Journal 5(5): A1378
Prepolec, M.; Wrone Smith, T.; Van Buren, E.; Lerman, S. 1992: Quantification and cell cycle analyses of rcs5 tumor cd4 positive and cd8 positive cells in cyclophosphamide cy treated tumor bearing sjl mice FASEB Journal 6(4): A1433
Li, L.; Okino, T.; Kan, N.; Yamasaki, S.; Ichinose, Y.; Sugie, T.; Kanaoka, S.; Imamura, M. 1998: Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide BioTherapy 11(4): 223-228
Shim, J.Y.; Han, Y.; Ahn, J.Y.; Yun, Y.S.; Song, J.Y. 2007: Chemoprotective and adjuvant effects of immunomodulator ginsan in cyclophosphamide-treated normal and tumor bearing mice International Journal of Immunopathology and Pharmacology 20(3): 487-497
Wu, Y.-P.; Deng, J.; Ouyang, S.-H.; Mao, Z.-F.; Wang, G.-E.; Kurihara, H.; He, R.-R.; Li, Y.-F. 2018: Immune regulation effect of lienal polypeptides extract in Lewis lung carcinoma-bearing mice treated with cyclophosphamide Experimental Biology and Medicine 243(1): 66-77
Yoshino, T.; Sato, K. 1992: Combination effect of KW-2228 and aminoglycoside antibiotics on systemic infection in cyclophosphamide-treated tumor-bearing mice Japanese Journal of Antibiotics 45(1): 98-105
Thrush, G.R.; Wrone, T.S.; Lerman, S.P. 1990: Cd8 cells from cyclophosphamide cy treated sjl j lymphoma bearing mice suppress cd4 proliferation to tumor in a class i mhc restricted manner FASEB Journal 4(7): A1945
Young, M.R.; Wright, M.A. 1992: Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis Cancer Research 52(22): 6335-6340
Lu, M.; Zhang, J.-j.; Cao, D.-m.; Zhao, X.-x.; Wang, G.-a.; Zhang, L. 2015: Effect of Acupuncture and Moxibustion Intervention on Contents of Serum Interleukin-7 and In- terleukin-18 in Cyclophosphamide-induced Immune Suppression in Tumor-bearing Mice Zhen Ci Yan Jiu 40(5): 396-401
Giraldi, T.; Sava, G.; Perissin, L.; Zorzet, S. 1984: Primary tumor growth and formation of spontaneous lung metastases in mice bearing Lewis carcinoma treated with proteinase inhibitors Anticancer Research 4(4-5): 221-224
Futami, H.; Jansen, R.; MacPhee, M.J.; Keller, J.; McCormick, K.; Longo, D.L.; Oppenheim, J.J.; Ruscetti, F.W.; Wiltrout, R.H. 1990: Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy Journal of Immunology 145(12): 4121-4130
Hosokawa, M.; Sawamura, Y.; Morikage, T.; Okada, F.; Xu, Z.Y.; Morikawa, K.; Itoh, K.; Kobayashi, H. 1988: Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide Cancer Immunology Immunotherapy: Cii 26(3): 250-256
Nonaka, Y.; Ishibashi, H.; Nakai, M.; Shibata, H.; Kiso, Y.; Abe, S. 2008: Effects of the antlered form of Ganoderma lucidum on tumor growth and metastasis in cyclophosphamide-treated mice Bioscience Biotechnology and Biochemistry 72(6): 1399-1408
Noso, Y.; Becker, J.; Riveau, G.; Audibert, F.; Chedid, L. 1990: Production and enhanced anti-tumor activity of tumor necrosis factor in mice treated with cyclophosphamide Japanese Journal of Cancer Research: Gann 81(9): 942-948
Noso, Y.; Becker, J.; Riveau, G.; Audibert, F.; Chedid, L. 1990: Production and enhanced anti-tumor acitivity of tumor necrosis factor in mice treated with cyclophosphamide Jpn. J. Cancer Res 81(9): 942-948
Mastino, A.; Favalli, C.; Grelli, S.; Rasi, G.; Pica, F.; Goldstein, A.L.; Garaci, E. 1992: Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice International Journal of Cancer 50(3): 493-499